Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy

References

• Raja S, Murthy SC, Mason DP. Malignant pleural mesothelioma. Curr Oncol Rep. 2011;13(4):259–264. 10.1007/s11912-011-0177-9
   PubMed Web of Science ®Google Scholar
• Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–496.
   PubMedGoogle Scholar
• Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475–488. 10.1038/nrc.2017.42
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial.Lancet. 2016;387(10026):1405–1414. 10.1016/S0140-6736(15)01238-6
   PubMed Web of Science ®Google Scholar
• Haas AR, Sterman DH. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. Clin Chest Med. 2013;34(1):99–111. 10.1016/j.ccm.2012.12.005
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2003;21(14):2636–2644. 10.1200/JCO.2003.11.136
   PubMed Web of Science ®Google Scholar
• Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O’Brien M, Thomas G, Senan S, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study.Lancet Oncol. 2011;12(8):763–772. 10.1016/S1470-2045(11)70149-8
   PubMed Web of Science ®Google Scholar
• Coulie PG, van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer. 2014;14(2):135–146. 10.1038/nrc3670
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature Reviews Cancer. 2016;16(4):219–233. 10.1038/nrc.2016.16
   PubMed Web of Science ®Google Scholar
• Lievense LA, Sterman DH, Cornelissen R, Aerts JG. Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2017;196:274–282. 10.1164/rccm.201608-1755CI
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med. 2015;373(17):1627–1639. 10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med. 2015;373(2):123–135. 10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med. 2015;373(19):1803–1813. 10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.N Engl J Med. 2016;375(19):1823–1833. 10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, et al. Metastatic melanoma - a review of current and future treatment options.Acta Derm Venereol. 2015;95(5):516–524. 10.2340/00015555-2035
   PubMed Web of Science ®Google Scholar
• Housseau F, Llosa NJ. Immune checkpoint blockade in microsatellite instable colorectal cancers: back to the clinic. Oncoimmunology. 2015;4(6):e1008858. 10.1080/2162402X.2015.1008858
   PubMed Web of Science ®Google Scholar
• Dobrzanski MJ. Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol. 2013;3:63. 10.3389/fonc.2013.00063
   PubMedGoogle Scholar
• Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, Aerts JG. Efficacy of tumor vaccines and cellular immunotherapies in non-small-cell lung cancer: a systematic review and meta-analysis.J Clin Oncol. 2016;34(26):3204–3212. 10.1200/JCO.2015.66.3955
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Veltman JD, Lambers ME, De Vries IJ, Figdor CG, Hendriks RW, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.Am J Respir Crit Care Med. 2010;181(12):1383–1390. 10.1164/rccm.200909-1465OC
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Aerts JG. Immunomodulation in cancer. Curr Opin Pharmacol. 2014;17:17–21. 10.1016/j.coph.2014.06.007
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:Suppl:S185-98. 10.1016/j.semcancer.2015.03.004
   Web of Science ®Google Scholar
• Bjoern J, Brimnes MK, Andersen MH, Thor Straten P, Svane IM. Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2. Scand J Immunol. 2011;73(3):222–233. 10.1111/j.1365-3083.2010.02494.x
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911. 10.1016/j.immuni.2009.03.019
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.Cancer Immunology, Immunotherapy: CII. 2015;64(10):1271–1286. 10.1007/s00262-015-1729-x
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006;27(6):1086–1095. 10.1183/09031936.06.00135305
   PubMed Web of Science ®Google Scholar
• Ireland DJ, Kissick HT, Beilharz MW, Ireland DJ, Kissick HT, Beilharz MW. The role of regulatory T cells in mesothelioma. Cancer Microenvironment: Official Journal of the International Cancer Microenvironment Society. 2012;5(2):165–172. 10.1007/s12307-012-0100-4
   PubMedGoogle Scholar
• McCoy MJ, Nowak AK, VanDer Most RG, Dick IM, Lake RA. Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunology, Immunotherapy: CII. 2013;62(3):529–539. 10.1007/s00262-012-1360-z
   PubMed Web of Science ®Google Scholar
• Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep. 2006;16(1):141–146.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.Cancer Immunology, Immunotherapy: CII. 2007;56(5):641–648. 10.1007/s00262-006-0225-8
   PubMed Web of Science ®Google Scholar
• Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, Okamoto M, Oka Oka. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 2012;32(12):5363–5369.
   PubMed Web of Science ®Google Scholar
• Heylmann D, Bauer M, Becker H, VanGool S, Bacher N, Steinbrink K, Kaina B. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response.PloS One. 2013;8(12):e83384. 10.1371/journal.pone.0083384
   PubMed Web of Science ®Google Scholar
• Veltman JD, Lambers ME, VanNimwegen M, De Jong S, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP. Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. J Biomed Biotechnol. 2010;2010:798467. 10.1155/2010/798467
   PubMedGoogle Scholar
• Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, Hendriks RW, Hoogsteden HC, Aerts JG. Extended tumor control after dendritic cell vaccination with low dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2015
   Web of Science ®Google Scholar
• Zhang S, Pan SB, Lyu QH, Wu P, Qin GM, Wang Q, He ZL, He XM, Wu M, Chen G. Postoperative regulatory T-cells and natural killer cells in stage i nonsmall cell lung cancer underwent video-assisted thoracoscopic lobectomy or thoracotomy.Chin Med J (Engl). 2015;128(11):1502–1509. 10.4103/0366-6999.157672
   PubMed Web of Science ®Google Scholar
• Chen C, Chen D, Zhang Y, Chen Z, Zhu W, Zhang B, Wang Z, Le H. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.Int Immunopharmacol. 2014;18(2):255–261. 10.1016/j.intimp.2013.12.004
   PubMed Web of Science ®Google Scholar
• Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.Cancer Immunol Immunother. 2012;61(3):353–362. 10.1007/s00262-011-1106-3
   PubMed Web of Science ®Google Scholar
• Wu J, Waxman DJ. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett. 2014;353(2):272–280. 10.1016/j.canlet.2014.07.033
   PubMed Web of Science ®Google Scholar
• Madondo MT, Quinn M, Plebanski M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev. 2016;42:3–9. 10.1016/j.ctrv.2015.11.005
   PubMed Web of Science ®Google Scholar
• Matar P, Rozados VR, Gervasoni SI, Scharovsky GO. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother. 2002;50(11):588–596. 10.1007/s00262-001-0237-3
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 2000;95(6):2024–2030.
   PubMed Web of Science ®Google Scholar
• Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.Clin Cancer Res. 2007;13(2 Pt 1):644–653. 10.1158/1078-0432.CCR-06-1209
   PubMed Web of Science ®Google Scholar
• Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka Jet al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.Oncotarget. 2015;6(20):18192–18205. 10.18632/oncotarget.4145
   PubMed Web of Science ®Google Scholar
• Liston A, Gray DHD. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14(3):154–165. 10.1038/nri3605
   PubMed Web of Science ®Google Scholar
• Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius E, Jackson SE, Salmon M, Falciani F, Yong K, Rustin MH, et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO.J Immunol. 2010;184(8):4317–4326. 10.4049/jimmunol.0903781
   PubMed Web of Science ®Google Scholar
• Wang C, Lee JH, Kim CH. Optimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switch. PloS One. 2012;7(1):e30793. 10.1371/journal.pone.0030793
   PubMed Web of Science ®Google Scholar
• Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, et al. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.Breast Cancer Res Treat. 2018;168(1):57–67. 10.1007/s10549-017-4570-4
   PubMed Web of Science ®Google Scholar
• Prieto GA, Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology. 2006;118(1):58–65. 10.1111/j.1365-2567.2006.02339.x
   PubMed Web of Science ®Google Scholar
• Sundar R, Cho B-C, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96. 10.1177/1758834014567470
   PubMed Web of Science ®Google Scholar
• Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):97–106. 10.1177/1758834014567469
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, E E, Kanakura Y, Sato E, Fukumori Yet al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.Proc Natl Acad Sci U S A. 2013;110(44):17945–17950. 10.1073/pnas.1316796110
   PubMed Web of Science ®Google Scholar
• Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, Oka M, Nakayama E. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).J Thorac Oncol. 2015;10(1):74–83. 10.1097/JTO.0000000000000364
   PubMed Web of Science ®Google Scholar